Study introduces TRACeR-I, a protein platform with broad HLA compatibility, paving the way for advanced immune response engineering and disease-specific targeting. Study: Targeting peptide antigens ...

The research team engineered CD8+ Jurkat T cells to express SVAR16, a human TCR with intermediate-to-high 2D affinity for the SARS-CoV-2-derived epitope HLAA2:01–YLQ, using lentiviral transduction.

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

Transplantation of organs or tissues between genetically nonidentical individuals of the same species (and different species) is plagued by rejection and its associated problems. "Foreignness" is ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

Although CAR T-cell therapies have reached significant clinical success in hematological malignancies, their utility in solid tumors remains limited. One of the main challenges is the scarcity of ...

Immunotherapy has revolutionized cancer treatment by harnessing the power of T cells to attack tumors. But, even when these treatments are successful, scientists often struggle to understand exactly ...

Cancer immunotherapy has completely changed our understanding of how cancer can and should be treated. A prime example is chimeric antigen receptor (CAR) T-cell therapy, where T cells are harvested ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Autoantibodies are antibodies that target the body’s own antigens. These antigens may consist of proteins, nucleic acids, carbohydrates, or lipids expressed ubiquitously throughout the body or only in ...